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Abstract
Background: Guidelines for the prevention of coronary heart disease (CHD) recommend use of Framingham-based risk
scores that were developed in white middle-aged populations. It remains unclear whether and how CHD risk prediction
might be improved among older adults. We aimed to compare the prognostic performance of the Framingham risk score
(FRS), directly and after recalibration, with refit functions derived from the present cohort, as well as to assess the utility of
adding other routinely available risk parameters to FRS.
Methods: Among 2193 black and white older adults (mean age, 73.5 years) without pre-existing cardiovascular disease from
the Health ABC cohort, we examined adjudicated CHD events, defined as incident myocardial infarction, CHD death, and
hospitalization for angina or coronary revascularization.
Results: During 8-year follow-up, 351 participants experienced CHD events. The FRS poorly discriminated between persons
who experienced CHD events vs. not (C-index: 0.577 in women; 0.583 in men) and underestimated absolute risk prediction
by 51% in women and 8% in men. Recalibration of the FRS improved absolute risk prediction, particulary for women. For
both genders, refitting these functions substantially improved absolute risk prediction, with similar discrimination to the
FRS. Results did not differ between whites and blacks. The addition of lifestyle variables, waist circumference and creatinine
did not improve risk prediction beyond risk factors of the FRS.
Conclusions: The FRS underestimates CHD risk in older adults, particularly in women, although traditional risk factors
remain the best predictors of CHD. Re-estimated risk functions using these factors improve accurate estimation of absolute
risk.
Citation: Rodondi N, Locatelli I, Aujesky D, Butler J, Vittinghoff E, et al. (2012) Framingham Risk Score and Alternatives for Prediction of Coronary Heart Disease in
Older Adults. PLoS ONE 7(3): e34287. doi:10.1371/journal.pone.0034287
Editor: Weili Zhang, FuWai hospital, Chinese Academy of Medical Sciences, China
Received January 8, 2012; Accepted February 26, 2012; Published March 28, 2012
Copyright:  2012 Rodondi et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: The authors have no support or funding to report.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: Nicolas.Rodondi@insel.ch
Introduction
Guidelines for the prevention of coronary heart disease (CHD)
recommend the use of risk scores to identify adults at higher risk of
CHD for whom preventive therapy–e.g., by lipid lowering drugs–
has higher absolute benefits [1]. Several scoring systems exist to
help clinicians assess the 10-year CHD risk [2,3,4], with the
Framingham risk score (FRS) [2] the most widely used. US
Guidelines for the prescription of lipid-lowering drug therapy [5]
and aspirin in primary prevention [6] are based on the risk
estimations provided by the FRS.
Most risk scores were developed in white middle-aged
populations [2,3,4]. Thus, it is uncertain whether risk estimates
based on these scores can be generalized to the elderly. The FRS,
for example, was developed in a white middle-aged population
with a mean age of 49 years and included persons as young as 30
and none older than 74 [2]. Actual risk prediction with FRS might
perform less well in older adults compared to middle-aged adults,
and some traditional risk factors have weaker associations with
CHD risk in the elderly; for example, total and LDL-cholesterol
are strong cardiovascular risk factors in middle-aged but not in
older adults [7].
As it remains unclear whether and how CHD risk prediction
might be improved in the growing population of elderly [8] to
facilitate primary prevention strategies, we aimed to compare the
prognostic performance of 1) the FRS, directly and 2) after
PLoS ONE | www.plosone.org 1 March 2012 | Volume 7 | Issue 3 | e34287recalibration [9], and 3) with functions derived from the Health
ABC Study, a cohort of elderly white and black men and women
[10]. We also aimed to assess 4) the utility of adding routinely
available lifestyle and simple laboratory variables not part of the
FRS but which have been shown to predict CHD in older adults,
such as creatinine [11], glucose [12] and lifestyle factors (alcohol
consumption [13], physical activity [14]).
Methods
Study population
Participants were part of the Health, Aging, and Body
Composition Study (Health ABC Study), a population-based
cohort of 3075 community-dwelling men and women, aged 70–79
during the study enrollment period in 1997–1998. Participants
were identified from a random sample of white and all black
Medicare-eligible adults living in designated zip codes areas
surrounding Pittsburgh, PA, and Memphis, TN. Eligibility criteria
at baseline included the ability to walk J mile, up 10 stairs
without rest and perform basic activities of daily living indepen-
dently [10]. All participants gave written informed consent and the
Pittsburgh and Memphis Institutional Review Boards approved
the protocol.
Among the 3075 participants, we excluded 841 who had overt
cardiovascular disease (CVD) at baseline, defined as diagnosis of
CHD (angina, prior myocardial infarction, angioplasty of
coronary arteries or coronary artery surgery), stroke or transient
ischemic attack, peripheral arterial revascularization, carotid
artery disease, heart failure or having a pacemaker. We also
excluded 41 participants with missing data for any of the
traditional cardiovascular risk factors. The final sample for our
analyses was 2193 participants.
Measurements
Cardiovascular risk factors. Participants reported smoking
history and were classified as never, current, or former smoker.
Fasting total cholesterol, HDL-cholesterol, and blood pressure
were measured as previously described [15]. Hypertension was
defined as self-report and use of anti-hypertensive medications, or
measured blood pressure $140 and/or $90 mm Hg. Diabetes
was defined as self-reported medical diagnosis and/or using any
hypoglycemic medication [16]. Physical activity was assessed by
questionnaire about all types of walking and exercise performed in
the prior week [14].
Cardiovascular events. During 8-year follow-up, we
assessed incident CHD events and mortality among participants
without overt CVD at baseline [16]. Using algorithms mirroring
those of the Cardiovascular Health Study [16], diagnoses and
cause of death were adjudicated until 2006–2007 based on
interview, review of all hospital records, death certificates, and
other documents by a panel of clinicians. CHD events included
nonfatal myocardial infarction or coronary death (corresponding
to ‘‘hard’’ events, as defined in the current FRS [5]), and
hospitalization for angina or revascularization (coronary
angioplasty or surgery) [17].
Statistical Analyses
The FRS predicts 10-year CHD risk based on a Cox model
estimated using data from the Framingham Heart Study [2]. The
Framingham cohort included 5345 subjects aged 30–74 years at
the time of their examination in 1971–1974. For this analysis, we
used the sex-specific Framingham equations of Wilson [2], because
they include diabetes, a strong independent CHD risk factor
[18,19]. This FRS Cox model includes age, total and HDL
cholesterol, blood pressure, diabetes, and smoking status.
In this study, we compared the prognostic performance of the
FRS, directly and after recalibration (taking into account different
prevalence of risk factors and underlying rates of developing
CHD), with functions entirely derived from the Health ABC
cohort, similar to previous studies [9]. Analyses were stratified by
gender. We first estimated the FRS using regression coefficient
estimates and values of the risk factor means reported by Wilson
[2]. To account for the shorter follow-up in the Health ABC study
and to avoid extrapolation beyond the range of the data [17], we
examined 7.5-year risk and adapted accordingly the estimated
baseline survival function used in computing the FRS. Participants
who died from non-CHD death were censored at the time of
death.
We then examined whether the predictive performance of the
FRS could be improved with recalibration or with refitting model
coefficients. For the recalibrated version of the FRS [9], we re-
estimated predicted risks for Health ABC by retaining the original
coefficient estimates reported by Wilson [2] but adapted the risk
factor means to the present cohort and the Kaplan Meier estimate
of the baseline survival function of Health ABC data. For the refit
version of the FRS (the ‘‘Health ABC function’’), we estimated the
regression coefficients with a Cox model fitted to the Health ABC
data, obtaining an estimated predicted risk entirely based on
Health ABC data. In this model, some adjacent risk factor
categories were combined to avoid cells with limited numbers of
events and/or unpredictive trends.
To compare prediction of these three risk models, we examined
different statistical measures. To assess discrimination, we used
Harrell’s C-index [20], an adaptation of the C-statistic an
adaptation of the C-statistic or area under the ROC curve for
use with survival data. As the model validation for Health ABC
functions was performed on the same dataset used for estimating
the Cox model and the sample included too few events for split-
sample validation, we calculated an optimism-corrected C-index
using bootstrap resampling [21] with 1000 replications [20]. To
assess model calibration, we used Parzen’s adaptation [22] of the
Hosmer-Lemeshow test to the Cox model.
In exploratory analysis, we sought to determine whether
alternative sets of predictors would improve risk prediction. To
evaluate the utility of adding to the FRS different lifestyle and
simple laboratory variables, we initially considered predictor
variables with p,0.20 in unadjusted Cox models for CHD events
in Health ABC data. We then used three model selection
procedures: a backward selection with a retention criterion of
p,0.10, and two forward stepwise selection procedures minimiz-
ing the Akaike Information Criterion (AIC) and the Bayesian
Information Criterion (BIC), respectively [23]. In these models,
total cholesterol, HDL-cholesterol, and blood pressure were
modeled as continuous predictors. Statistical analyses were
performed using the software R, version 2.9.1 (R Foundation for
Statistical Computing, Vienna, Austria).
Results
At baseline, the mean age of the study participants was 73.5
years; 55% were women, and 41% were black (Table 1). The
mean 10-year risk based on the FRS was 14.9%. Most participants
had a 10-year CHD risk ranging from 5 to 19.9%.
During a median follow-up of 8.3 years (maximum, 10.2 years),
351 participants developed a CHD event (197 of which had a
‘‘hard’’ CHD event). In unadjusted analyses, all traditional
cardiovascular risk factors were associated with CHD events
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Variable Mean ± SD / n (%) HR (95% CI) p
Age 73.5062.85 1.03 (1.00, 1.07) 0.09
Age (categories) 0.03*
70–71 672 (30.6)
72–75 934 (42.6) 0.99 (0.77, 1.27)
76–78 464 (21.2) 1.05 (0.78, 1.41)
79 123 (5.6) 1.59 (1.04, 2.43)
Gender
Men 981 (44.7)
Women 1212 (55.3) 0.52 (0.42, 0.65) ,0.001
Race
White 1293 (59.0)
Black 900 (41.0) 0.96 (0.78, 1.19) 0.73
Site
Memphis 1125 (51.3)
Pittsburgh 1068 (48.7) 0.99 (0.79, 1.22) 0.89
Education 0.29*
,high school 532 (24.3)
High school graduate 734 (33.6) 0.81 (0.61, 1.07)
Postsecondary 922 (42.1) 0.87 (0.67, 1.13)
Smoking status 0.03*
Never 1016 (46.3)
Former 956 (43.6) 1.41 (1.13, 1.77)
Current 221 (10.1) 1.49 (1.04, 2.12)
Alcohol, drinks/wk 0.41*
,1 1535 (70.3)
1–7 482 (22.1) 0.88 (0.68, 1.14)
.7 166 (7.6) 1.17 (0.81, 1.70)
Physical activity, kcal/wk
{ 0.20*
,500 1148 (52.3)
500–1500 598 (27.3) 0.96 (0.74, 1.23)
$1500 447 (20.4) 1.18 (0.91, 1.54)
Hypertension{ 1258 (57.4) 1.28 (1.03, 1.59) 0.02
Diabetes mellitus 292 (13.3) 1.63 (1.24, 2.13) ,0.001
Body mass index, kg/m
2 27.4164.91 1.02 (1.00, 1.04) 0.10
Abdominal circumference 99.43613.54 1.01 (1.00, 1.02) 0.02
Systolic blood pressure, per 10 mmHg 135.72620.63 1.09 (1.04, 1.15) ,0.001
Diastolic blood pressure, per 10 mmHg 71.59611.66 1.12 (1.02, 1.22) 0.01
Total cholesterol, per 10 mg/dl 204.83637.93 0.99 (0.96, 1.01) 0.31
HDL-cholesterol, per 10 mg/dl 55.46617.12 0.87 (0.81, 0.93) ,0.001
Total/HDL-cholesterol 3.9861.22 1.15 (1.06, 1.25) ,0.001
LDL-cholesterol, per 10 mg/dl 122.87634.44 1.01 (0.98, 1.04) 0.50
Triglycerides, mg/dlI 116 (87–160) 1.11 (0.89, 1.39) 0.36
Glucose, per 10 mg/dl 102.46631.88 1.05 (1.03, 1.08) ,0.001
Framingham risk score, %" ,0.001
,5% 468 (21.3)
5–9.99% 557 (25.4) 1.35 (0.92, 1.99)
10–19.99% 543 (24.8) 2.12 (1.47, 3.04)
$20% 625 (28.5) 3.06 (2.17, 4.31)
Creatinine, mg/dlI 1 (0.9–1.1) 1.96 (1.33, 2.87) 0.001
GFR, ml/min/1.73 m
2# 61.15615.05 1.00 (0.99, 1.01) 0.87
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Abdominal circumference, glucose, and creatinine were also
associated with CHD events, but not glomerular filtration rate,
alcohol use or physical activity levels. Results were similar for hard
CHD events with larger confidence intervals because of lower
number of events (data not shown), except that the association
with abdominal circumference disappeared (HR=1.00).
Number of participants in different risk factor categories and
CHD events are shown in Table 2 for women and Table 3 for
men. The original FRS had poor discrimination in these older
adults (C-index: 0.577 in women; 0.583 in men). Using risk factors
as continuous variables yielded similar C-indexes. Calibration of
the original FRS was also poor in older adults (Figure 1),
particularly among women, for whom the absolute risk was
underestimated by 51% (vs. 8% in men, Table S1). Recalibration
of the FRS improved calibration, particularly for women, and
produced a better match between observed and expected CHD
risk (Figure 1, Table S1). Statistically significant differences
between observed and expected risks across deciles remained, at
least in in women (p value remaining ,0.05, larger p-values
indicating better calibration), with an overestimation of the
predicted risk for those above the median risk by a factor of 1.4
for women and 1.3 for men. For both genders, the Health ABC
function significantly improved calibration (Figure 1). For
discrimination, the C-index for the Health ABC function, after
correction for optimism, was comparable to the C-index of the
FRS (p=0.54 for women and 0.90 for men, Tables 2 and 3). Total
cholesterol and age
2 were not predictive in women and were
therefore omitted in the Health ABC function. Overall, results did
not differ between whites and blacks. C-indexes for the unmodified
FRS, the recalibrated FRS and the Health ABC function stratified
by gender did not significantly differ between whites and blacks (all
p for interaction .0.20; C-indexes ranging from 0.550 to 0.603).
Calibration became reasonable (with p.0.20 for comparison of
observed with expected) in white men for the unmodified FRS and
in white men and women for the recalibrated FRS, but the best
calibration remained for the Health ABC function (p.0.20 for
comparison of observed with expected in the four subgroups
stratified by race and gender).
We used a variety of model selection procedures when
considering the addition of routinely available measures not
included in the Framingham risk factor set to the Health ABC
function. The procedures based on p-values and the AIC lead to
very similar final models (Table S2); in contrast, the BIC, which
strongly penalizes the complexity of the model, lead to the
omission of a larger number of risk factors. All final models mainly
retained traditional risk factors included in the FRS. The additions
of lifestyle variables (alcohol, physical activity), waist circumfer-
ence, and creatinine did not improve risk prediction in terms of
discrimination or model fit beyond using the traditional risk factors
from the FRS. Selection procedures stratified by gender yielded
similar results.
Discussion
In this population-based study of older adults, the FRS poorly
discriminated between persons who experienced a CHD event and
those who did not (C-index: 0.577 in women; 0.583 in men) and
underestimated the absolute CHD risk by 51% in women and 8%
in men. Nevertheless, traditional risk factors remained the best
predictors of CHD events. Physical activity, alcohol consumption,
waist circumference and creatinine did not improve risk prediction
beyond traditional risk factors of the FRS. Recalibration of the
FRS improved the accuracy of absolute risk estimation, particu-
larly for women. For both genders, the Health ABC function
significantly improved estimation of absolute risk, with a
discrimation similar to the FRS. Neither refitting equations nor
including other routinely available measurements in risk equations
provided substantial benefits in terms of discriminating between
high- and low-risk older adults over FRS.
Our study adds new data on the performance of recalibration of
the FRS, refit functions and the utility of adding other routinely
Table 1. Cont.
Variable Mean ± SD / n (%) HR (95% CI) p
GFR (categories)
** 0.63
$80 525 (23.9) 1.00
70–79.99 536 (24.5) 1.11 (0.83,1.49)
60–69.99 555 (25.3) 0.87 (0.64,1.18)
,60 576 (26.3) 1.00 (0.75,1.35)
Medication use
Lipid-lowering 229 (10.4) 1.04 (0.75, 1.46) 0.79
Ace inhibitors 273 (12.4) 1.14 (0.84, 1.54) 0.39
Hormone replacement therapy 48 (2.2) 0.82 (0.37, 1.85) 0.64
Aspirin 412 (18.8) 1.31 (1.02, 1.69) 0.03
Abbreviations: SD: standard deviation; HR: hazard ratio; CI: confidence interval; HDL: high-density lipoprotein; LDL: low-density lipoprotein; GFR: glomerular filtration
rate.
*p for trend.
{Physical activity was assessed by questionnaire about all types of walking and exercise performed in the prior week [14].
{Defined by self-report of hypertension and use of anti-hypertensive medications, or measured SBP$140 and/or DBP$90 mmHg.
IExpressed as median (25%–75%), because of skewed distribution. The effect of the logarithm of the covariates on the CHD is measured.
"Classes of CHD risk at 10 years, according to Framingham functions [2].
#Glomerular filtration rate (GFR) was estimated using the MDRD equation: GFR=175 * Creatinine
21.154 * Age
20.203 * (1.212*Iblack+Iwhite)* (0.742*Ifemale+Imen) [32].
**Quartiles were used instead of clinical cut-offs to avoid categories with few participants. In particular, categories of GFR,15 and within 15–29.99 were collapsed with
the category 30–59.99 (only 0.2% in the class of GFR,15 and 0.5% in the class of GFR within 15–29.99) and a $80 category was replaced to the usual $90 (only 7% for
GFR$90).
doi:10.1371/journal.pone.0034287.t001
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studies also found lower performance of risk prediction based on
the FRS associated with increasing age, but did not examine how
CHD risk prediction might be improved among older adults. For
example, the C-index for the FRS was 0.63/0.66 in men/women
aged 65–74 enrolled in the Cardiovascular Health Study [24] and
0.63 in a patient cohort with a mean age of 66 years [25],
compared to 0.79/0.83 in men/women enrolled in the Framing-
ham Heart Study (mean age of 49 years) [24]. Performance of the
FRS may be worse in the very old, with a C-index of 0.53 in adults
aged 85 years or older [26]. In different ethnic populations in the
US and other countries, FRS often overestimates CHD risk
Table 2. Discrimination and calibration of Framingham functions (FRS), recalibrated FRS and Health ABC function in women
(n=1212).
Participants with
Risk Factor, N (%)
CHD events
(N) FRS Recalibrated FRS Refit FRS (Health ABC function )*
Coef
{ Coef
{ Coef (95%CI) HR (95% CI)
Age, y, mean (SD) 73.41 (2.84) 146 0.33766 0.33766 0.00 (20.06,0.06) 1.00 (0.95,1.06)
Age
2 20.00268 20.00268
TC, mg/dL{
,160 78 (6%) 11 20.26138 20.26138
160–199 364 (30%) 46 Referent Referent
200–239 496 (41%) 52 0.20771 0.20771
240–279 217 (18%) 29 0.24385 0.24385
$280 57 (5%) 8 0.53513 0.53513
HDL-C, mg/dL{
,35 21 (2%) 2 0.84312 0.84312 0.21 (20.30,0.71) 1.23 (0.74 ,2.04)
35–44 149 (12%) 22 0.37796 0.37796
45–49 149 (12%) 21 0.19785 0.19785 0.14 (20.39,0.67) 1.15 (0.68,1.95)
50–59 322 (27%) 41 Referent Referent Referent Referent
$60 571 (47%) 60 20.42951 20.42951 20.10 (20.51,0.30) 0.90 (0.60,1.35)
Blood pressureI
Optimal 266 (22%) 19 20.53363 20.53363 20.26 (20.86,0.33) 0.77 (0.42,1.40)
Normal 259 (21%) 25 Referent Referent Referent Referent
High normal 254 (21%) 38 20.06773 20.06773 0.41 (20.09,0.92) 1.51 (0.91,2.51)
Stage I hypertension 296 (24) 46 0.26288 0.26288 0.45 (20.02,0.91) 1.56 (0.98,2.49)
Stage II–IV hypertension 137 (11%) 18 0.46573 0.46573
Diabetes 141 (12%) 27 0.59626 0.59626 0.62 (0.20,1.05) 1.86 (1.22,2.85)
Smoker
Never 714 (59%) 83 Referent Referent Referent Referent
Former 388 (32%) 48
Current 110 (9%) 15 0.29246 0.29246 0.29 (20.25,0.83) 1.34 (0.78,2.29)
Mean survival function at
t=7.5 years, S0(t)
0.9717" 0.8898# 0.8962**
C-index 0.577 0.577 0.598{{
H-L statisticsII 121.43 (,0.001) 22.73 (0.007) 7.96 (0.539)
Abbreviations: FRS: Framingham risk score; CHD: coronary heart disease; coef: coefficient; CI: confidence interval; SD: standard deviation; TC: total cholesterol; HDL-C:
high-density lipoprotein cholesterol.
*Some of the Framingham risk factors categories were collapsed to avoid cells with limited numbers of events and /or unpredictive trends. Total cholesterol and age
2
were omitted because they were unpredictive in these older women. The proportionality assumption was tested using the Therneau and Grambsch statistics, which is
based on the Schoenfeld residuals. The assumption was accepted (p=0.14).
{Based on Wilson et al. [2].
{Cholesterol categories proposed by the National Cholesterol Education Program [24].
IBlood pressure categories: Optimal (Systolic,120, Diastolic.80); Normal (Systolic,130, Diastolic.85); High normal (Systolic,140, Diastolic.90); Stage I
(Systolic,160, Diastolic,100); Stage II–IV (Systolic $160, Diastolic $100) [24].
"Estimated from the Framingham adjusted survival rate (survival rate at the mean value of the risk factors) at 10 years: S0(10)=0.96246 [2], as: S ˆ0(7.5)=S0(10)
0.75=0.9717
(exponential model).
#Kaplan-Meier survival function at t=7.5 years on HABC data, similar to reference [24].
**Adjusted survival rate at t=7.5 years obtained on the HABC cohort as the baseline survival functions of the multivariate Cox model, similar to reference [9].
{{After bootstrap correction for the optimism (1000 bootstrap samples from the original dataset [20]), c-index=0.564 (p=0.54 for comparison with Framingham
function).
II Adaptation to the Cox model of the Hosmer-Lemeshow test of goodness of fit [33], comparing observed and expected failures within deciles of predicted risk. Larger
p values indicate better calibration [21].
doi:10.1371/journal.pone.0034287.t002
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estimation of absolute risk in these different ethnic populations
[9,24]. In the present analysis among older adults, the FRS
underestimated absolute CHD risk, particularly in women.
Although recalibration of the FRS yielded a better estimation of
absolute risk, the function specific to the Health ABC cohort
yielded the best estimation of absolute risk, becoming statistically
acceptable. Compared to recalibration among other ethnic groups
[9,24], the recalibrated FRS showed worse risk prediction in our
study of older adults. Our results indicate that the FRS not only
underestimates CHD risk in older adults but that some traditional
risk factors, such as total and LDL-cholesterol, have weaker
associations with CHD risk in older adults, as previoulsy found [7].
In particular, total cholesterol did not predict CHD events in older
women in our present study.
Our study has several strengths and limitations. These data are
drawn from a well-characterized population-based cohort of older
adults, with a high number of CHD events over a 8-year follow-up
Table 3. Discrimination and calibration of Framingham functions (FRS), recalibrated FRS and Health ABC function in men (n=981).
Participants with
Risk Factor, N (%)
CHD events
(N) FRS Recalibrated FRS Refit FRS (Health ABC function )*
Coef
{ Coef
{ Coef (95% CI) HR (95% CI)
Age, y, mean (SD) 73.613 (2.86) 205 0.04826 0.04826 0.05 (20.00,0.10) 1.05 (1.00,1.10)
TC, mg/dL{
,160 139 (14%) 23 20.65945 20.65945 20.32 (20.78,0.14) 0.73 (0.46,1.15)
160–199 451 (46%) 94 Referent Referent Referent Referent
200–239 303 (31%) 69 0.17692 0.17692
240–279 70 (7%) 15 0.50539 0.50539 0.10 (20.20,0.39) 1.10 (0.82,1.48)
$280 18 (2%) 4 0.65713 0.65713
HDL-C, mg/dL{
,35 140 (14%) 28 0.49744 0.49744
35–44 295 (30%) 72 0.24310 0.24310 Referent Referent
45–49 160 (16%) 38 Referent Referent
50–59 204 (21%) 40 20.05107 20.05107 20.23 (20.58,0.13) 0.80 (0.56,1.13)
$60 182 (19%) 27 20.48660 20.48660 20.60 (21.02 ,20.19) 0.55 (0.36,0.83)
Blood pressureI
Optimal 214 (22%) 27 20.00226 20.00226 20.47 (20.95,0.02) 0.63 (0.39,1.02)
Normal 210 (22%) 42 Referent Referent Referent Referent
High normal 188 (19%) 51 0.28320 0.28320
Stage I hypertension 258 (26%) 59 0.52168 0.52168 0.18 (20.16,0.53) 1.20 (0.85,1.70)
Stage II–IV hypertension 111 (11%) 26 0.61859 0.61859
Diabetes 151 (15%) 38 0.42839 0.42839 0.23 (20.12,0.58) 1.26 (0.88,1.79)
Smoker
Never 302 (31%) 56 Referent Referent Referent Referent
Former 568 (58%) 125
Current 111 (11%) 24 0.52337 0.52337 0.28 (20.15,0.71) 1.32 (0.86,2.03)
Mean survival function at
t=7.5 years, S0(t)
0.9241" 0.7929# 0.8032**
C-index 0.583 0.583 0.606{{
H-L statisticsII 16.27 (0.062) 16.11 (0.065) 4.89 (0.844)
Abbreviations: FRS: Framingham risk score; CHD: coronary heart disease; coef: coefficient; CI: confidence interval; SD: standard deviation; TC: total cholesterol; HDL-C:
high-density lipoprotein cholesterol.
*Some of the Framingham risk factors categories were collapsed to avoid cells with limited numbers of events and /or unpredictive trends. The proportionality
assumption was tested using the Therneau and Grambsch statistics, which is based on the Schoenfeld residuals. The assumption was accepted (p=0.33).
{Based on Wilson et al. [2].
{Cholesterol categories proposed by the National Cholesterol Education Program [24].
IBlood pressure categories: Optimal (Systolic,120, Diastolic.80); Normal (Systolic,130, Diastolic.85); High normal (Systolic,140, Diastolic.90); Stage I
(Systolic,160, Diastolic,100); Stage II–IV (Systolic $160, Diastolic $100) [24].
"Estimated from the Framingham adjusted survival rate (survival rate at the mean value of the risk factors) at 10 years: S0(10)=90015 [2], as: S ˆ0(7.5)=S0(10)
0.75=0.9241
(exponential model).
#Kaplan-Meier survival function at t=7.5 years on HABC data, similar to reference [24].
**Adjusted survival rate at t=7.5 years obtained on the HABC cohort as the baseline survival functions of the multivariate Cox model, similar to reference [9].
{{After bootstrap correction for the optimism (1000 bootstrap samples from the original dataset [20]), c-index=0.580 (p=0.90 for comparison with Framingham
function).
II Adaptation to the Cox model of the Hosmer-Lemeshow test of goodness of fit [33], comparing observed and expected failures within deciles of predicted risk. Larger
p values indicate better calibration [21].
doi:10.1371/journal.pone.0034287.t003
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compared to previous studies [24]. CHD events were formally
adjudicated. The cohort included both white and black older
adults, but did not include other ethnic groups. After stratification
by gender, our power for subgroup analyses was limited for
comparisons between whites and blacks. Lower performance of
the FRS might partly be related to ascertainment of CHD events
limited to those requiring hospitalization in the Health ABC, but
not in the Framingham cohort [2]. However, all our comparisons
in the present data examined CHD outcomes limited to those
requiring hospitalization; we also found similar associations for
hard CHD events (nonfatal myocardial infarction or coronary
death).
What are the potential clinical and research implications of
these findings? Clinicians should use the FRS with caution in older
adults, as it underestimates the absolute CHD risk by 51% in
women and 8% in men and does not discriminate effectively
between those who will have CHD events and those who will not.
We could not identify additional, routinely available variables that
might improve risk prediction beyond traditional risk factors
comprising the FRS, similar to several previous studies that did not
clearly identify factors improving risk prediction of the FRS [28].
Re-estimated risk functions using these factors improve accurate
estimation of absolute risk, but did not meaningfully improve
discrimination, or the ability to distinguish between low,
intermediate, and high-risk adults. Substantial improvements in
discrimination may require novel CHD risk markers or other
strategies for risk prediction in the elderly. We have previously
found that ankle-arm index and interleukin-6, but not high-
sensitive C-reactive protein, improved risk prediction beyond
traditional risk factors, but only modestly [17]. Other potential
markers that might improve CHD risk prediction in the elderly
include homocysteine [26] or coronary calcification [29]. Future
investigations should examine whether markers of atherosclerosis
[29] or novel CHD risk markers [30] might improve risk
prediction beyond FRS in older adults, which still requires
additional studies [31]. For current clinical use, recalibrated
Framingham functions seem an attractive option to better assess
absolute CHD risk for older adults (Methods S1), given that no
currently available new risk factors have been clearly and
consistently shown to improve CHD risk prediction [28] and that
the Health ABC function needs to be externally validated in
another cohort.
In summary, our study suggests that the FRS underestimates
CHD risk in the growing population of elderly [8], particularly in
older women. However, traditional risk factors remain the best
predictors of future CHD events. Recalibrating risk functions in
older adults is important to improve the accuracy of absolute
CHD risk estimates, especially for women, and might be useful to
better identify older individuals at increased risk who will benefit
from preventive therapies, such as statins or aspirin. However,
substantial improvements in discrimination may require novel
Figure 1. Predicted risk of CHD events at 7.5 years according to original Framingham functions, recalibrated Framingham functions
and Health ABC functions.
doi:10.1371/journal.pone.0034287.g001
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prediction and risk stratification in the elderly.
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